

Editorial

The Plasma Membrane: A Catalyst in the Decision to Die or not to Die?

DEATH RECEPTOR-MEDIATED CELL DEATH

Induction of cell death plays a crucial role in morphogenesis, homeostasis, immune tolerance and surveillance and chemotherapy. Supernumerary, damaged, transformed, or infected cells can be eliminated through intrinsic or extrinsic cell death programs. The induction of the extrinsic signal occurs when cytokines (i.e., CD95L, TRAIL, TNF- α) present in serum or anchored in immune cells (e.g., T-lymphocytes, natural killer cells) bind to their respective death receptors, namely CD95 (also called APO-1 or Fas), DR4 and DR5 or TNF-R1. Interaction with the ligand orchestrates aggregation and conformational alteration of the death receptors, whose intracellular domains recruit adaptor proteins (i.e., TRADD, FADD), which in turn drive, through protein/protein interactions, the induction of caspases evoking the death program.

PLASMA MEMBRANE AND “DEATH RECEPTOR” SIGNALING PATHWAYS

The extensive characterization of the protein/protein interactions promoting the ignition of the apoptotic signal, led to underestimate the role played by the lipid bilayer plasma membrane in the signaling induced by death receptors. In this regard, death receptors are anchored into a 3-D support, the plasma membrane, which exhibits a complex structure and exerts constraints affecting receptor motility, aggregation, conformation and consequently signaling. Recent evidences established that not only the lipid composition of the membrane bilayer, but also the partition of the death receptors into subdomains designated lipid rafts, detergent-resistant membranes (DRMs), or merely microdomains may affect the transmission of the apoptotic pathway. For instance, distribution of CD95 into lipid rafts dramatically enhances the induction of the signal [1-6]. More strikingly, not only the ligand fixation is able to redistribute CD95 into lipid rafts, but also different anti-tumoral agents have been reported to achieve the partition of CD95 into large platforms constituted of aggregated lipid rafts [2, 7-12]. It is noteworthy that the reorganization of CD95 into DRMs can occur independently of its ligand upon addition of certain chemotherapeutic drugs (e.g., rituximab [13], resveratrol [9, 14], edelfosine [7, 11], apilidin [15], perifosine [16], cisplatin [12]). The molecular mechanisms that underlie this process remain to be elucidated. Nevertheless, the current evidence let us to envision that intracellular signal(s) or modulation of the plasma membrane biophysical properties mimic the death cytokine-driven initial events [17].

It is noteworthy that designation of these receptors as “death receptors” originated from initial studies that were seeking for apoptotic inducers [18, 19]. However, this appellation leads to a misunderstanding since all death receptors are able to induce non-apoptotic signals that, in certain context, promote carcinogenesis [20-23]. While theoretically speaking, decrease in the apoptotic threshold has been reported to switch the CD95 signal from a non-apoptotic to an apoptotic signaling pathway [24-26], it remains to identify the molecular mechanism(s) underlying this phenomenon. Endocytosis of CD95 may reduce the apoptotic threshold and thereby, may discriminate between apoptosis and non-apoptosis signaling. Indeed, cells harboring a mutation in the AP-2-binding motif of CD95 (e.g., Y291F) were not only unable to internalize the death receptor and to transmit the apoptotic signal, but they also continued to induce non-apoptotic signals in the presence of CD95L [27]. In this topic issue, Milosavljenic and colleagues reported that endocytosis relies on the forces applied on the membrane and thus, on the composition of the membrane itself. Consequently, we may envision that the plasma membrane composition, which diverges between normal and tumor cells, controls the fate of the CD95 signal, even if the role of endocytosis in death receptor signaling remains controversial [28, 29]. Likewise, the partition of CD95 into aggregated lipid rafts, whose micrometer-sized structure accumulates and/or excludes critical death modulators, may alternatively contribute to modulating the apoptotic threshold and thus, the cell fate. The partition of death receptors together with downstream apoptotic signaling molecules in aggregated DRMs [15, 16, 30-32] has led to the emerging concept of “liquid-ordered” plasma membrane platform designated as “cluster of apoptotic signaling molecule-enriched rafts” (CASMER) [33]. These CASMERs may reduce the apoptotic signal threshold by stabilizing protein/protein interactions and thereby, catalyze the transmission of the apoptotic signal [33].

BIOPHYSICAL PROPERTIES OF THE PLASMA MEMBRANE AND “DEATH RECEPTOR” SIGNALING PATHWAYS

Another parameter regulating the biophysical properties of plasma membrane and its composition is the intracellular pH, which in turn alters the induction of the apoptotic signal induced upon death receptor engagement. Indeed, reduction of the intracellular pH not only modulates the plasma membrane composition by activating acidic sphingomyelinase, which in turn generates ceramides, but also promotes protonation of the lipid polar heads present in the inner leaflet. This latter effect reduces membrane packing and tension, which both influence drug permeation and membrane endocytosis, affecting the amounts of chemotherapeutic drugs retained in tumor cells and the death receptor signaling, respectively. In addition, numerous pollutants alter the biophysical properties of the plasma membrane through the production of reactive oxygen species (ROS), which in turn enhance lipid peroxidation [34], activate acid sphingomyelinase [35], and modulate gene expression involved in lipid metabolism, and thus modify plasma membrane composition.

In agreement with these notions, the fine regulation of ceramide synthesis (balance between hydrolysis of sphingomyelin and *de novo* biosynthesis) should be an essential player in promoting or impeding both immune response (death receptor

signaling) and chemotherapy outcome (death receptor signaling and drug retention). In this regard, numerous patents cover the association of the apoptotic cytokines (*i.e.*, CD95L, TRAIL, TNF) or chemotherapeutic regimens with ceramide or its derivatives in order to re-sensitize malignant cells to death [36-43]. Nevertheless, it remains to define the appropriate length of the fatty acid linked to the sphingosine backbone, that will structurally impact the plasma membrane conformation in order to enhance endocytosis, accumulate drugs inside tumor cells, and/or catalyze the apoptotic signal triggered by death receptors.

This thematic issue tempts to provide some new insight into the potential chemotherapeutical roles of CD95 and TRAIL-R signaling pathways and their modulation by the biophysical properties of the plasma membrane.

ACKNOWLEDGEMENTS

P.L.'s team is supported by grants from Institut National du Cancer (Projets libres en recherche biomédicale CALPROTCD95), ANR (JC07_183182 and SphingoDR), Cancéropole GO, Région Bretagne, Rennes Métropole, Université de Rennes-1, and Ligue Contre le Cancer (Comités d'Ille-et-Vilaine/Morbihan/Côtes d'Armor/Maine et Loire). F.M.'s team is supported by grants from Ministerio de Ciencia e Innovación of Spain (SAF2008-02251, and RD06/0020/1037 from Red Temática de Investigación Cooperativa en Cáncer, Instituto de Salud Carlos III, cofunded by the Fondo Europeo de Desarrollo Regional of the European Union), European Community's Seventh Framework Programme FP7-2007-2013 (grant HEALTH-F2-2011-256986), and Junta de Castilla y León (CSI052A11-2, GR15-Experimental Therapeutics and Translational Oncology Program, and Biomedicine Project 2009).

REFERENCES

- [1] Cremesti A, Paris F, Grassme H, Holler N, Tschopp J, Fuks Z, *et al.* Ceramide enables fas to cap and kill. *J Biol Chem* 2001; 276: 23954-61.
- [2] Eramo A, Sargiacomo M, Ricci-Vitiani L, Todaro M, Stassi G, Messina CG, *et al.* CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells. *Eur J Immunol* 2004; 34: 1930-40.
- [3] Hueber AO, Bernard AM, Herincs Z, Couzinet A, He HT. An essential role for membrane rafts in the initiation of Fas/CD95-triggered cell death in mouse thymocytes. *EMBO Rep* 2002; 3: 190-6.
- [4] Legembre P, Daburon S, Moreau P, Ichas F, de Giorgi F, Moreau JF, *et al.* Amplification of Fas-mediated apoptosis in type II cells via microdomain recruitment. *Mol Cell Biol* 2005; 25: 6811-20.
- [5] Legembre P, Daburon S, Moreau P, Moreau JF, Taupin, JL. Cutting edge: Modulation of fas-mediated apoptosis by lipid rafts in T lymphocytes. *J Immunol* 2006; 176: 716-20.
- [6] Scheel-Toellner D, Wang K, Singh R, Majeed S, Raza K, Curnow SJ, *et al.* The death-inducing signalling complex is recruited to lipid rafts in Fas-induced apoptosis. *Biochem Biophys Res Commun* 2002; 297: 876-9.
- [7] Beneteau M, Pizon M, Chaigne-Delalande B, Daburon S, Moreau P, De Giorgi F, *et al.* Localization of Fas/CD95 into the lipid rafts on down-modulation of the phosphatidylinositol 3-kinase signaling pathway. *Mol Cancer Res* 2008; 6: 604-13.
- [8] Chaigne-Delalande B, Moreau JF, Legembre P. Rewinding the DISC. *Arch Immunol Ther Exp (Warsz)* 2008; 56: 9-14.
- [9] Delmas D, Rebe C, Mîcheau O, Athias A, Gambert P, Grazide S, *et al.* Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. *Oncogene* 2004; 23: 8979-86.
- [10] Gajate C, Del Canto-Janez E, Acuna AU, Amat-Guerri F, Geijo E, Santos-Beneit AM, *et al.* Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. *J Exp Med* 2004; 200: 353-65.
- [11] Gajate C, Mollinedo F. The antitumor ether lipid ET-18-OCH₃ induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. *Blood* 2001; 98: 3860-3.
- [12] Lacour S, Hammann A, Grazide S, Lagadic-Gossmann D, Athias A, Sergent O, *et al.* Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. *Cancer Res* 2004; 64: 3593-8.
- [13] Stel AJ, Ten Cate B, Jacobs S, Kok JW, Spierings DC, Dondorf M, *et al.* Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis. *J Immunol* 2007; 178: 2287-95.
- [14] Delmas D, Rebe C, Lacour S, Filomenko R, Athias A, Gambert P, *et al.* Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. *J Biol Chem* 2003; 278: 41482-90.
- [15] Gajate C, Mollinedo F. Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. *J Biol Chem* 2005; 280: 11641-7.
- [16] Gajate C, Mollinedo F. Edelfosine and perfosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. *Blood* 2007; 109: 711-9.
- [17] Segui B, Legembre P. Redistribution of CD95 into the lipid rafts to treat cancer cells? *Recent Pat Anticancer Drug Discov* 2010; 5: 22-8.
- [18] Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, *et al.* Monoclonal antibody-mediated tumor regression by induction of apoptosis. *Science* 1989; 245: 301-5.
- [19] Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, *et al.* The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. *Cell* 1991; 66: 233-43.
- [20] Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, *et al.* CD95 promotes tumour growth. *Nature* 2010; 465: 492-6.
- [21] Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Geiffers C, Hill O, *et al.* Yes and PI3K bind CD95 to signal invasion of glioblastoma. *Cancer Cell* 2008; 13: 235-48.
- [22] Letellier E, Kumar S, Sancho-Martinez I, Krauth S, Funke-Kaiser A, Laudenklos S, *et al.* CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site. *Immunity* 2010; 32: 240-52.
- [23] O' Reilly LA, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD, *et al.* Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. *Nature* 2009; 461: 659-63.
- [24] Lavrik IN, Golks A, Riess D, Bentele M, Eils R, Krammer PH. Analysis of CD95 threshold signaling: Triggering of CD95 (FAS/APO-1) at low concentrations primarily results in survival signaling. *J Biol Chem* 2007; 282: 13664-71.
- [25] Legembre P, Barnhart BC, Peter ME. The relevance of NF-kappaB for CD95 signaling in tumor cells. *Cell Cycle* 2004; 3: 1235-9.
- [26] Legembre P, Barnhart BC, Zheng L, Vijayan S, Straus SE, Puck J, *et al.* Induction of apoptosis and activation of NF-kappaB by CD95 require different signalling thresholds. *EMBO Rep* 2004; 5: 1084-9.
- [27] Lee KH, Feig C, Tchikov V, Schickel R, Hallas C, Schutze S, *et al.* The role of receptor internalization in CD95 signaling. *Embo J* 2006; 25: 1009-23.
- [28] Chaigne-Delalande B, Mahfouf W, Daburon S, Moreau JF, Legembre P. CD95 engagement mediates actin-independent and -dependent apoptotic signals. *Cell Death Differ* 2009; 16: 1654-64.

- [29] Kohlhaas SL, Craxton A, Sun XM, Pinkoski MJ, Cohen GM. Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. *J Biol Chem* 2007; 282: 12831-41.
- [30] Gajate C, Gonzalez-Camacho F, Mollinedo F. Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. *PLoS ONE* 2009; 4: e5044.
- [31] Mollinedo F, de la Iglesia-Vicente J, Gajate C, Estella-Hermoso de Mendoza A, Villa-Pulgarin JA, Campanero MA, *et al.* Lipid raft-targeted therapy in multiple myeloma. *Oncogene* 2010; 29: 3748-57.
- [32] Reis-Sobreiro M, Gajate C, Mollinedo F. Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions. *Oncogene* 2009; 28: 3221-34.
- [33] Mollinedo F, Gajate C. Lipid rafts, death receptors and CASMERS: New insights for cancer therapy. *Future Oncol* 2010; 6: 491-4.
- [34] Ghosh C, Dick RM, Ali SF. Iron/ascorbate-induced lipid peroxidation changes membrane fluidity and muscarinic cholinergic receptor binding in rat frontal cortex. *Neurochem Int* 1993; 23: 479-84.
- [35] Charruyer A, Grazide S, Bezombes C, Muller S, Laurent G, Jaffrezou JP. UV-C light induces raft-associated acid sphingomyelinase and JNK activation and translocation independently on a nuclear signal. *J Biol Chem* 2005; 280: 19196-204.
- [36] Chatterjee, S.B. Neutral sphingomyelinase antisense ribozyme and uses thereof. US7230094 (2007).
- [37] Dagan, A., Slavin, S., Gatt, S., Zahavi, J. Novel synthetic analogs of sphingolipids. US0034542 (2011).
- [38] Kolesnick, R. Method for the modulation of acid-sphingomyelinase-related apoptosis. US6274309 (2001).
- [39] Kolesnick, R., Schuchman, E.H. Methods and compositions for the modulation of acid-sphingomyelinase-related apoptosis. US6790627 (2004).
- [40] Liotta, D., Merrill, A., Keane, T., Schmelz, E., Bhalla, K. Sphingolipid derivatives and their methods of use. EP1053243 (2011).
- [41] Modrak, D. Sphingomyelin enhancement of tumor therapy. US6541462 (2003).
- [42] Modrak, D., Goldenberg, D. Sphingomyelin therapy of autoimmune disease. US7683044 (2010).
- [43] Wanebo, J., Mehta, S. Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer. US7820718 (2010).

Patrick Legembre

Université de Rennes-1,
IRSET/ EA-4427 SERAIC,
2 Avenue du Professeur Léon Bernard,
35043, Rennes,
France
E-mail: patrick.legembre@inserm.fr

Faustino Mollinedo

Instituto de Biología Molecular y Celular del Cáncer,
Centro de Investigación del Cáncer,
CSIC-Universidad de Salamanca,
Campus Miguel de Unamuno,
E-37007 Salamanca,
Spain.
E-mail: fmollin@usal.es